^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Calsed (amrubicin)

    i
    Other names: CNF3140, S 5887, SM-5887, CNF-3140, S-5887, SM5887, CNF 3140, S5887, SM 5887
    Associations

    News

    Trials
    Company:
    BMS, Nippon Kayaku, Sumitomo Pharma
    Drug class:
    Topoisomerase II inhibitor
    Related drugs:
    Associations

    News

    Trials
    26d
    IDeate-Lung02: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=540, Recruiting, Daiichi Sankyo | Active, not recruiting --> Recruiting
    Enrollment open
    |
    topotecan • Zepzelca (lurbinectedin) • ifinatamab deruxtecan (DS-7300) • Calsed (amrubicin)
    1m
    A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=531, Not yet recruiting, AbbVie
    New P3 trial • Adverse events
    |
    topotecan • Zepzelca (lurbinectedin) • ABBV-706 • Calsed (amrubicin)
    4ms
    IDeate-Lung02: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=540, Active, not recruiting, Daiichi Sankyo | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    topotecan • Zepzelca (lurbinectedin) • ifinatamab deruxtecan (DS-7300) • Calsed (amrubicin)
    5ms
    IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer. (PubMed, Future Oncol)
    Patients with small cell lung cancer (SCLC) have poor prognosis and limited treatment options beyond first-line therapy. Secondary endpoints include ORR by investigator; progression-free survival, duration of response, disease control rate, and time to response, all by BICR and investigator; patient-reported outcomes; and safety. IDeate-Lung02 will ascertain whether I-DXd treatment after only one prior line of systemic treatment improves outcomes for patients with relapsed SCLC compared with topotecan, amrubicin, or lurbinectedin.Clinical Trial Registration: NCT06203210.
    P3 data • Journal
    |
    CD276 (CD276 Molecule)
    |
    topotecan • Zepzelca (lurbinectedin) • ifinatamab deruxtecan (DS-7300) • Calsed (amrubicin)
    8ms
    DeLLphi-304: Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=509, Active, not recruiting, Amgen | Trial completion date: Jul 2027 --> Mar 2028
    Trial completion date
    |
    topotecan • Zepzelca (lurbinectedin) • Imdelltra (tarlatamab-dlle) • Calsed (amrubicin)
    10ms
    DeLLphi-304: Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=509, Active, not recruiting, Amgen | Trial primary completion date: Jul 2027 --> Jan 2025
    Trial primary completion date
    |
    topotecan • Zepzelca (lurbinectedin) • Imdelltra (tarlatamab-dlle) • Calsed (amrubicin)
    12ms
    EVOKE-SCLC-04: Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=695, Recruiting, Gilead Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Trodelvy (sacituzumab govitecan-hziy) • topotecan • Calsed (amrubicin)
    over1year
    DeLLphi-304: Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=509, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    topotecan • Zepzelca (lurbinectedin) • Imdelltra (tarlatamab-dlle) • Calsed (amrubicin)
    over1year
    IDeate-2: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=468, Recruiting, Daiichi Sankyo | Not yet recruiting --> Recruiting
    Enrollment open
    |
    topotecan • Zepzelca (lurbinectedin) • ifinatamab deruxtecan (DS-7300) • Calsed (amrubicin)
    almost2years
    IDeate-2: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=468, Not yet recruiting, Daiichi Sankyo | Trial completion date: Jan 2028 --> Feb 2029 | Trial primary completion date: Jul 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    topotecan • Zepzelca (lurbinectedin) • ifinatamab deruxtecan (DS-7300) • Calsed (amrubicin)
    2years
    DeLLphi-304: Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=490, Recruiting, Amgen | N=700 --> 490 | Trial primary completion date: Sep 2025 --> Aug 2027
    Enrollment change • Trial primary completion date
    |
    topotecan • Zepzelca (lurbinectedin) • Imdelltra (tarlatamab-dlle) • Calsed (amrubicin)
    2years
    A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=468, Not yet recruiting, Daiichi Sankyo, Inc.
    New P3 trial
    |
    topotecan • Zepzelca (lurbinectedin) • ifinatamab deruxtecan (DS-7300) • Calsed (amrubicin)